Truist Securities Reiterates Vertex (VRTX) at Buy, $341 PT, Sees Potential Upside From Upcoming Crispr's Diabetes Read-Through
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $341.00 price target on Vertex (NASDAQ: VRTX) in light of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
